MIRM - Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc.
950 Tower Lane
Suite 1050
Foster City, CA 94404
United States
650 667 4085
https://www.mirumpharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 200
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Christopher Peetz | Pres, CEO & Director | 1.09M | N/A | 1979 |
| Mr. Peter Radovich M.B.A., Ph.D. | Chief Operating Officer | 732.15k | N/A | 1978 |
| Dr. Pamela Vig Ph.D. | Head of R&D | 678.2k | N/A | 1971 |
| Ms. Lara Longpre MBA, MSC | Chief Devel. Officer | 678.2k | N/A | 1970 |
| Jolanda Howe | Sr. VP & Global Controller | N/A | N/A | N/A |
| Mr. Paul K. Ross | Chief Compliance Officer | N/A | N/A | N/A |
| Ms. Erin Campany | Sr. VP of HR | N/A | N/A | 1968 |
| Dr. Ian Clements Ph.D. | Consultant | N/A | N/A | 1969 |
| Ms. Vinita P. Kumar | Sr. vice Pres of Quality | N/A | N/A | N/A |
| Dr. Jean-Luc Girardet Ph.D. | Sr. VP of Technical Operations | N/A | N/A | N/A |
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of primary sclerosing cholangitis and primary biliary cholangitis in adults. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Corporate Governance
Mirum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2023 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.
